HK1139681A1 - Salts of valsartan - Google Patents

Salts of valsartan

Info

Publication number
HK1139681A1
HK1139681A1 HK10105932.8A HK10105932A HK1139681A1 HK 1139681 A1 HK1139681 A1 HK 1139681A1 HK 10105932 A HK10105932 A HK 10105932A HK 1139681 A1 HK1139681 A1 HK 1139681A1
Authority
HK
Hong Kong
Prior art keywords
valsartan
salts
Prior art date
Application number
HK10105932.8A
Other languages
English (en)
Inventor
Erwin Marti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1139681A1 publication Critical patent/HK1139681A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
HK10105932.8A 2002-02-04 2010-06-14 Salts of valsartan HK1139681A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35419902P 2002-02-04 2002-02-04

Publications (1)

Publication Number Publication Date
HK1139681A1 true HK1139681A1 (en) 2010-09-24

Family

ID=27734333

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10105932.8A HK1139681A1 (en) 2002-02-04 2010-06-14 Salts of valsartan

Country Status (18)

Country Link
US (3) US6869970B2 (fr)
EP (1) EP1474402A1 (fr)
JP (2) JP4895475B2 (fr)
KR (3) KR20110101257A (fr)
CN (2) CN100548993C (fr)
AU (1) AU2003214054B2 (fr)
BR (1) BR0307442A (fr)
CA (2) CA2474424C (fr)
CO (1) CO5611107A2 (fr)
EC (1) ECSP045221A (fr)
HK (1) HK1139681A1 (fr)
MX (1) MXPA04007525A (fr)
NO (1) NO328155B1 (fr)
NZ (1) NZ534560A (fr)
PL (1) PL370481A1 (fr)
RU (1) RU2004126862A (fr)
WO (1) WO2003066606A1 (fr)
ZA (1) ZA200405698B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
SI1515717T1 (sl) * 2002-06-13 2009-02-28 Novartis Ag Kalcijeve soli statinov, izvedenih iz indola
DE602004013405T2 (de) * 2003-03-17 2009-05-07 Teva Pharmaceutical Industries Ltd. Polymorphe formen von valsartan
JP4783733B2 (ja) * 2003-05-16 2011-09-28 ノバルティス アーゲー バルサルタンを含む医薬組成物
WO2005046677A2 (fr) * 2003-11-14 2005-05-26 Novartis Ag Utilisation pharmaceutique supplementaire
ITMI20032267A1 (it) * 2003-11-21 2005-05-22 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procdimento per la preparzione di valsartan e suoi intermedi
WO2005049587A1 (fr) * 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Procede de preparation de tetrazole de biphenyle
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
DE502004002443D1 (de) * 2004-04-15 2007-02-08 Helm Ag Verfahren zur Herstellung von freifliessenden, pulverförmigen Valsartan-Adsorbaten
AR050043A1 (es) * 2004-08-03 2006-09-20 Novartis Ag Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares
WO2006021443A2 (fr) * 2004-08-26 2006-03-02 Novartis Ag Composes organiques
EP1806137A4 (fr) * 2004-10-29 2011-03-30 Kowa Co Agent thérapeutique contre les maladies glomérulaires
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2008035364A2 (fr) * 2006-06-23 2008-03-27 Usv Limited Procédé de préparation de valsartan micronisé
AR061627A1 (es) 2006-06-27 2008-09-10 Novartis Ag Formas de dosificacion solidas de valsartan, amlodipina, e hidroclorotiazida, y metodo para elaborarlas
WO2008018843A1 (fr) * 2006-08-08 2008-02-14 Ulkar Kimya Sanayi Ve Ticaret As Procédé de production de formes de sel utiles de composés de biphényl-tétrazole
PE20080907A1 (es) * 2006-08-31 2008-08-22 Novartis Ag Sistema de suministro de farmaco oral gastro-retentivo de liberacion extendida para valsartan
WO2008088727A2 (fr) 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Antagonistes du récepteur de l'endothéline
US8080549B2 (en) * 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
CN101396366B (zh) * 2007-09-25 2010-10-13 浙江华海药业股份有限公司 含缬沙坦的固体口服制剂及其制备方法
ES2336755B1 (es) * 2008-10-07 2011-01-21 Activery Biotech, S.L. Procedimiento para la preparacion de combinaciones de valsartan y simvastatina.
JP2011063518A (ja) * 2009-09-15 2011-03-31 Tohoku Univ Ａｒｂ及び／又はグリタゾン系血糖降下物質を含有するｏａｔｐ−ｒ遺伝子発現増強組成物
MX2013001251A (es) 2010-08-03 2013-03-18 Novartis Ag Valsartan altamente cristalino.
CN103012301B (zh) * 2013-01-05 2015-06-17 江苏施美康药业股份有限公司 缬沙坦甲酯碱金属盐及其制备方法
DE102014004512A1 (de) * 2014-03-28 2015-10-01 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bereich Universitätsmedizin Anorganisch-organische Hybridverbindung
WO2017012600A1 (fr) 2015-07-20 2017-01-26 Zentiva, K.S. Composition pharmaceutique contenant du valsartan et du sacubitril et procédés de préparation et de stabilisation correspondants
WO2018002673A1 (fr) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii
EP3498698A1 (fr) 2017-12-15 2019-06-19 Mankind Pharma Ltd Formes solides de valsartan disodium et son procédé de préparation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59107440D1 (de) * 1990-02-19 1996-04-04 Ciba Geigy Ag Acylverbindungen
MX9707683A (es) * 1995-04-07 1997-12-31 Novartis Ag Composiciones de combinacion que contienen benazepril o benazeprilat y valsartan.
ES2099031B1 (es) 1995-05-31 1997-12-01 Esteve Labor Dr Nuevos polimorfos de diclorhidrato de lesopitron y sus formas hidratadas, procedimientos de preparacion y composiciones que los contienen.
US5877193A (en) * 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
AP9901660A0 (en) * 1997-02-28 1999-09-30 Burstein Lab Inc Laboratory in a disk.
US6641886B1 (en) * 1999-03-23 2003-11-04 Flexplay Technologies, Inc. Directory read inhibitor for optical storage media
JP2001155346A (ja) * 1999-11-26 2001-06-08 Toshiba Corp 情報記録媒体、情報記録装置、情報記録方法、情報再生装置、情報再生方法
HUP0300701A2 (hu) 2000-04-24 2003-07-28 Teva Pharmaceutical Industries Ltd. Zolpidem hemitartarát, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények
US20020132839A1 (en) * 2000-06-22 2002-09-19 Ganter Sabina Maria Tablet formulations comprising valsartan
PE20020613A1 (es) 2000-07-19 2002-08-07 Novartis Ag Sales de (s)-n-(1-carboxi-2-metil-prop-1-il)-n-pentanoil-n-[2'-(1h-tetrazol-5-il)-bifenil-4-ilmetil]-amina como antagonista del receptor at1
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan

Also Published As

Publication number Publication date
ECSP045221A (es) 2004-09-28
AU2003214054A1 (en) 2003-09-02
CN1628106A (zh) 2005-06-15
PL370481A1 (en) 2005-05-30
RU2004126862A (ru) 2005-06-27
CN101633646B (zh) 2012-08-29
US6869970B2 (en) 2005-03-22
CA2474424C (fr) 2013-03-26
MXPA04007525A (es) 2004-11-10
KR20120054667A (ko) 2012-05-30
AU2003214054B2 (en) 2007-08-16
CN100548993C (zh) 2009-10-14
KR20040081178A (ko) 2004-09-20
WO2003066606A1 (fr) 2003-08-14
KR20110101257A (ko) 2011-09-15
CO5611107A2 (es) 2006-02-28
US20120022268A1 (en) 2012-01-26
US8058301B2 (en) 2011-11-15
CA2776902A1 (fr) 2003-08-14
BR0307442A (pt) 2005-01-04
CN101633646A (zh) 2010-01-27
JP4895475B2 (ja) 2012-03-14
CA2474424A1 (fr) 2003-08-14
US20030171414A1 (en) 2003-09-11
JP2009235086A (ja) 2009-10-15
US8329919B2 (en) 2012-12-11
US20050101652A1 (en) 2005-05-12
JP5303370B2 (ja) 2013-10-02
EP1474402A1 (fr) 2004-11-10
ZA200405698B (en) 2006-05-31
JP2005517696A (ja) 2005-06-16
NO20043660L (no) 2004-10-12
NO328155B1 (no) 2009-12-21
NZ534560A (en) 2007-05-31

Similar Documents

Publication Publication Date Title
HK1139681A1 (en) Salts of valsartan
HUS1900052I1 (hu) 2-acilaminotiazol-származékok vagy sóik
ZA200500621B (en) 2-cyano-4-fluoropyrrolidine derivative or its salt
EP1558585A4 (fr) Composes neurologiquement actifs
GB0209022D0 (en) Compounds
GB0200283D0 (en) Compounds
AU2003214112A1 (en) Salts of nateglinide
IL169505A0 (en) Novel anticonvulsant derivatives salts
AU2003216859A8 (en) Amidoacetonitrile compounds
PL373794A1 (en) New salts
GB0207323D0 (en) Compounds
PL382044A1 (pl) Preparat zawierający walsartan
GB0203778D0 (en) Compounds
AU2003275480A8 (en) Compounds
GB0203811D0 (en) Compounds
HUP0203929D0 (en) New use of substituted alkyl-piridazinone derivatives
PL356853A1 (en) Application of bacteriphages
GB0218809D0 (en) Salts of morphine-6-glucuronide
GB0206981D0 (en) Compounds
GB0207286D0 (en) Salt
GB0206255D0 (en) Novel salt forms
GB0218043D0 (en) New use of diaza-anthracene compounds
GB0217750D0 (en) New use of diaza-anthracene compounds
SI1537210T1 (sl) Lazna oligonukleotidna inhibicija ekspresije CD40
GB0203735D0 (en) Anti-malarial compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170203